Study guide

11.2 Antifungal, Antiviral & Antiparasitic Therapeutics

APMLE Part I Basic Sciences Podiatry

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Lower Extremity Osteology

1.1 APMLE Part I Exam Structure, Policies & Scoring 1.2 Foot Osteology: Tarsals, Metatarsals, Phalanges & Sesamoids 1.3 Leg & Ankle Osteology: Tibia, Fibula & The Ankle Mortise 1.4 Pelvis, Femur & Patella Osteology: Landmarks & Biomechanics

2 Chapter 2: Lower Extremity Arthrology & Ligaments

2.1 Foot Articulations: Subtalar, Midtarsal, Lisfranc & Digital Joints 2.2 Talocrural (Ankle) & Knee Joints: Ligaments & Kinematics 2.3 Hip Joint & Pelvic Articulations: Capsular Structures & Dynamics

3 Chapter 3: Lower Extremity Myology & Compartments

3.1 Anterior & Lateral Compartments of the Leg 3.2 Superficial & Deep Posterior Compartments of the Leg 3.3 Plantar Layers & Intrinsic Musculature of the Foot 3.4 Thigh & Gluteal Musculature: Attachments & Innervations

4 Chapter 4: Lower Extremity Neurovascular & Topographical Anatomy

4.1 Lumbar & Sacral Plexuses, Peripheral Nerves & Dermatomes 4.2 Arterial Network, Venous Drainage & Lymphatics 4.3 Tarsal Tunnel, Femoral Triangle & Topographical Spaces

5 Chapter 5: Microbiology: Bacteriology, Zoonoses & Laboratory Methods

5.1 Gram-Positive Cocci & Bacilli in Podiatric Infections 5.2 Gram-Negative Bacilli & Opportunistic Pathogens 5.3 Anaerobic Pathogens & Diabetic Foot Infections 5.4 Bacterial Structure, Virulence Factors & Sterilization 5.5 Mycobacteria, Spirochetes, Mycoplasma & Zoonotic Infections 5.6 Antimicrobial Resistance, Susceptibility Testing, Specimen Handling & Vaccines

6 Chapter 6: Mycology, Virology, Parasitology & Clinical Immunology

6.1 Mycology: Dermatophytes, Onychomycosis & Systemic Mycoses 6.2 Clinically Relevant Viruses & Parasitic Infections 6.3 Innate & Adaptive Immunity Mechanisms 6.4 Hypersensitivity Reactions, Immunodeficiencies & Autoimmunity 6.5 Transplant & Tumor Immunology and Immunodiagnostic Methods

7 Chapter 7: General & Cellular Pathology

7.1 Cellular Injury, Adaptations & Cell Death Mechanisms 7.2 Acute vs Chronic Inflammation & Tissue Repair 7.3 Hemodynamic Disorders, Thrombosis, Embolism & Shock 7.4 Neoplasia, Oncogenes, Tumor Suppressors & Cutaneous Tumors

8 Chapter 8: Systemic & Podiatric Pathology

8.1 Atherosclerosis, Peripheral Artery Disease & Diabetic Microangiopathy 8.2 Osteoarthritis, Inflammatory Arthritides & Bone Infections 8.3 Neuropathic Disorders, Charcot Neuroarthropathy & Dermatopathology 8.4 Laboratory Diagnostics, Synovial Fluid & Biopsy Interpretation

9 Chapter 9: Organ-System Pathology

9.1 Anemias, Hemoglobinopathies, Leukemias & Immune Disorders 9.2 Cardiac & Pulmonary Pathology 9.3 Renal, Urogenital & Reproductive Pathology 9.4 Gastrointestinal, Hepatobiliary & Endocrine Pathology

10 Chapter 10: General Pharmacology, Autonomic Drugs & Toxicology

10.1 Pharmacokinetics, ADME & Receptor Dynamics 10.2 Cholinergic Agonists & Muscarinic/Nicotinic Antagonists 10.3 Adrenergic Agonists, Sympatholytics & Clinical Applications 10.4 Cardiovascular Pharmacology in Podiatric Patients 10.5 Drug Interactions, Adverse Effects, Pharmacogenomics & Toxicology

11 Chapter 11: Antimicrobial & Podiatric Therapeutics

11.1 Antibacterial Classes, Mechanisms & Resistances 11.2 Antifungal, Antiviral & Antiparasitic Therapeutics 11.3 NSAIDs, Opioids, Corticosteroids & Anti-Gout Agents 11.4 Local & General Anesthetic Pharmacology

12 Chapter 12: Systemic Pharmacology

12.1 Anticonvulsants, Antidepressants, Psychotropics & Skeletal Muscle Relaxants 12.2 Insulin & Noninsulin Glycemic Agents 12.3 Respiratory & Gastrointestinal Agents 12.4 DMARDs, Biologics, Antineoplastics & Immunosuppressants 12.5 Hormone Therapy, Bisphosphonates, Antihistamines, Growth Factors & Complementary Agents

13 Chapter 13: General Anatomy: Systemic Gross Anatomy & Neuroanatomy

13.1 Cranial Nerves, Head & Neck Anatomy 13.2 Thoracic Wall, Tracheobronchial Tree, Lungs & Mediastinum 13.3 Abdominal Wall, GI Viscera, Pelvis & Retroperitoneum 13.4 Vertebral Column, Spinal Cord & Upper Extremity Overview 13.5 Neuroanatomy: CNS Organization, Somatosensory & Motor Pathways

14 Chapter 14: Histology, Integument, Embryology & Genetics

14.1 Microscopic Anatomy: Epithelia, Connective Tissue, Muscle & Nerve 14.2 Integumentary System: Dermis, Appendages, Nail Unit & Cutaneous Receptors 14.3 Embryogenesis, Limb Morphogenesis & Postnatal Development 14.4 Medical Genetics & Structural Alterations in Aging

15 Chapter 15: Cellular, Neuromuscular & Cardiovascular Physiology

15.1 Membrane Potential, Ion Channels & Transport Mechanisms 15.2 Action Potentials, Synaptic Transmission & Muscle Contraction 15.3 Cardiac Electrophysiology, ECG & Hemodynamics 15.4 Blood Pressure Regulation, Poiseuille Law & Capillary Dynamics

16 Chapter 16: Organ-System Physiology: Respiratory, Renal, Endocrine, GI & Blood

16.1 Pulmonary Mechanics, Gas Exchange & Acid-Base Regulation 16.2 Renal Filtration, Tubular Transport & Fluid/Acid-Base Balance 16.3 Endocrine Regulation, Reproductive Hormones, Calcium & Bone 16.4 Gastrointestinal & Hepatobiliary Physiology 16.5 Hematology: Erythropoiesis, Leukocytes, Platelets & Coagulation 16.6 Exercise Physiology, Thermoregulation & Bone Mechanobiology

17 Chapter 17: Biochemistry: Proteins, Enzymes, Carbohydrates & Signaling

17.1 Amino Acid Chemistry, Protein Structure & Enzyme Kinetics 17.2 Glycolysis, Gluconeogenesis, Glycogen Metabolism & TCA Cycle 17.3 Electron Transport Chain, ATP Synthesis & Metabolic Inborn Errors 17.4 Hormones, Receptors, Second Messengers & Signal Transduction

18 Chapter 18: Biochemistry: Lipids, Molecular Genetics, Blood Chemistry & Nutrition

18.1 Fatty Acid Oxidation, Ketogenesis, Cholesterol & Lipoproteins 18.2 Nucleotide Metabolism, DNA Replication, Transcription, Translation & Repair 18.3 Vitamins, Micronutrients & Inborn Errors of Metabolism 18.4 Blood Chemistry: Heme Metabolism, Hemoglobin & Plasma Proteins 18.5 Nutrition: Energy Balance, Glycemic Index, Fed-Fast Cycle & Free Radicals

11.2 Antifungal, Antiviral & Antiparasitic Therapeutics

Key Takeaways Explain This Topic AI

Terbinafine is the oral gold-standard fungicidal therapy for dermatophyte onychomycosis, acting via non-competitive inhibition of squalene epoxidase; toxic squalene accumulation causes fungal cell lysis, requiring baseline and periodic liver function tests (LFTs).

Azole antifungals (imidazoles and triazoles) inhibit fungal cytochrome P450 lanosterol 14-alpha-demethylase (ERG11 gene), blocking ergosterol synthesis; triazoles are potent CYP3A4 inhibitors and itraconazole carries a black box warning for negative inotropy in congestive heart failure.

Polyenes (amphotericin B, nystatin) bind directly to membrane ergosterol to create ion-leaking pores; amphotericin B exhibits severe nephrotoxicity with renal potassium and magnesium wasting, whereas nystatin is limited strictly to topical/oral mucosal use.

Topical onychomycosis formulations bypass systemic hepatotoxicity: ciclopirox 8% chelates polyvalent metal cations, efinaconazole 10% provides low keratin affinity for enhanced subungual penetration, and tavaborole 5% inhibits fungal leucyl-tRNA synthetase.

Acyclovir and its prodrug valacyclovir require monophosphorylation by viral thymidine kinase (TK) before host kinases produce the active triphosphate that terminates viral DNA polymerase; verruca plantaris (HPV) is managed by keratolytics (salicylic acid), vesicants (cantharidin), and TLR7 immunomodulators (imiquimod).

Last updated: October 2026

11.2 Antifungal, Antiviral & Antiparasitic Therapeutics

Independent Study Guide Notice: Independent study guide by ExamFinch. This educational resource is developed independently by ExamFinch and is not sponsored, endorsed, or affiliated with the National Board of Podiatric Medical Examiners (NBPME) or Meazure Learning.

Overview of Fungal & Viral Targets in Podiatry

Cutaneous fungal infections ( tinea pedis ) and onychomycosis represent the most prevalent dermatologic complaints encountered in podiatric practice, affecting up to 10% of the general population and over 30% of diabetic patients. The primary etiologic agents are dermatophytes—predominantly Trichophyton rubrum ( > 80 % >80\% > 80% ), Trichophyton mentagrophytes , and Epidermophyton floccosum —followed by non-dermatophyte molds ( Scopulariopsis brevicaulis , Fusarium ) and yeasts ( Candida albicans ).

Unlike human eukaryotic cells that utilize cholesterol as the primary membrane sterol, fungal cell membranes utilize ergosterol . Exploiting the unique enzymes in the fungal ergosterol biosynthesis pathway provides high therapeutic selectivity.

Squalene → Inhibited by Terbinafine Squalene Epoxidase Lanosterol → Inhibited by Azoles 14 α -Demethylase (CYP51) Ergosterol → Targeted by Polyenes Direct Binding Membrane Pores \text{Squalene} \xrightarrow[\textbf{Inhibited by Terbinafine}]{\text{Squalene Epoxidase}} \text{Lanosterol} \xrightarrow[\textbf{Inhibited by Azoles}]{\text{14}\alpha\text{-Demethylase (CYP51)}} \text{Ergosterol} \xrightarrow[\textbf{Targeted by Polyenes}]{\text{Direct Binding}} \text{Membrane Pores} Squalene Squalene Epoxidase Inhibited by Terbinafine ​ Lanosterol 14 α -Demethylase (CYP51) Inhibited by Azoles ​ Ergosterol Direct Binding Targeted by Polyenes ​ Membrane Pores

  • Ergosterol Synthesis Inhibitors: Allylamines & Azoles
  • 1. Allylamines: Terbinafine (Lamisil)

Terbinafine is a synthetic allylamine and represents the oral drug of choice (first-line therapy) for dermatophyte onychomycosis.

Mechanism of Action: Terbinafine is a non-competitive, reversible inhibitor of Squalene Epoxidase (squalene monooxygenase). Squalene epoxidase converts squalene to squalene-2,3-epoxide, an obligate precursor to lanosterol and ergosterol. Inhibition yields a dual effect:

Deficiency of ergosterol: Compromises fungal cell membrane structural integrity.

Toxic intracellular accumulation of squalene: Causes lipid droplet accumulation, membrane permeabilization, cellular organelle disruption, and rapid fungicidal cell lysis .

Dosing in Podiatry:

Toenail Onychomycosis: 250 mg 250\text{ mg} 250 mg orally once daily for 12 weeks 12\text{ weeks} 12 weeks .

Fingernail Onychomycosis: 250 mg 250\text{ mg} 250 mg orally once daily for 6 weeks 6\text{ weeks} 6 weeks .

Pharmacokinetics: Highly lipophilic and keratophilic; concentrates in the nail matrix, nail bed, and sebum, persisting in the distal nail plate for months following treatment cessation.

High-Yield Adverse Effects:

Hepatotoxicity: Drug-induced liver injury ranging from asymptomatic transaminitis to fulminant cholestatic jaundice and hepatic necrosis. Mandatory baseline Liver Function Tests (LFTs: ALT, AST) must be obtained prior to initiation, with repeat monitoring at 4 to 6 weeks.

Taste and Smell Disturbances (Dysgeusia / Ageusia / Anosmia): Can occur abruptly and persist for months after drug withdrawal; patients must be warned immediately.

Drug-Induced Lupus Erythematosus (DILE) & Cutaneous Lupus: Induces positive anti-histone antibodies and subacute cutaneous lupus erythematosus (SCLE).

Severe Cutaneous Reactions: Stevens-Johnson syndrome, erythema multiforme, and exacerbation of plaque psoriasis.

Few CYP3A4 interactions compared with azoles, but terbinafine is a strong CYP2D6 inhibitor that raises levels of tricyclic antidepressants, metoprolol and other CYP2D6 substrates.

2. Azole Antifungals: Imidazoles & Triazoles

Azoles are heterocyclic compounds classified by the number of nitrogen atoms in the azole ring:

Imidazoles (2 nitrogens): Ketoconazole, Clotrimazole, Miconazole, Econazole, Sertaconazole. (Largely relegated to topical use due to systemic toxicity and high human CYP450 inhibition).

Triazoles (3 nitrogens): Itraconazole, Fluconazole, Voriconazole, Posaconazole, Isavuconazole. (Enhanced metabolic stability, greater selectivity for fungal CYP over human CYP, primary systemic agents).

Mechanism of Action

Azoles competitively inhibit the fungal cytochrome P450-dependent enzyme Lanosterol 14- α \alpha α -demethylase (encoded by the E R G 11 ERG11 ERG 11 or CYP51 gene). This blocks the demethylation of lanosterol into 14-desmethyl lanosterol, halting ergosterol production. Toxic 14-methylsterols accumulate in the fungal membrane, destabilizing the lipid bilayer, inhibiting membrane-bound enzymes, and stunting fungal growth ( predominantly fungistatic ).

Drug Classification & Route Spectrum & Podiatric Application High-Yield Board Pearls & Toxicities

Itraconazole (Sporanox) Triazole (Oral/IV) Broad: Dermatophytes, Candida , Aspergillus , Histoplasma , Blastomyces . Alternative for onychomycosis. Dosing: Pulse therapy ( 200 mg 200\text{ mg} 200 mg BID for 1 week/month; 3 pulses for toenails) vs Continuous ( 200 mg 200\text{ mg} 200 mg daily for 12 weeks). Black Box Warning: Negative Inotropy — contraindicated in patients with ventricular dysfunction or Congestive Heart Failure (CHF) . Requires gastric acid for absorption. Potent CYP3A4 inhibitor .

Fluconazole (Diflucan) Triazole (Oral/IV) Candida albicans , Cryptococcus neoformans ; off-label once-weekly dosing for onychomycosis ( 150 − 300 mg 150 - 300\text{ mg} 150 − 300 mg weekly for 6–9 months). High water solubility , excellent urinary and CSF penetration. Cleared renally ( 80 % 80\% 80% unchanged; requires renal dose adjustment). Potent inhibitor of CYP2C9 (dramatically elevates Warfarin INR) and moderate CYP3A4 inhibitor. Inactive against Candida krusei and resistant Candida glabrata .

Voriconazole (Vfend) Triazole (Oral/IV) Drug of choice for Invasive Aspergillosis ; broad mold coverage ( Fusarium , Scedosporium ). High-yield adverse effects: Transient visual disturbances (photopsia, altered color perception in ∼ 30 % \sim 30\% ∼ 30% ), visual hallucinations, and severe photosensitivity leading to squamous cell carcinoma of the skin with prolonged therapy. Inhibits CYP2C19, CYP2C9, CYP3A4.

Ketoconazole (Nizoral) Imidazole (Topical/Oral) Broad topical dermatophyte and Malassezia furfur (tinea versicolor) coverage. Oral use is abandoned due to severe fatal hepatotoxicity and potent non-selective inhibition of human steroid synthesis enzymes ( 17 , 20 17,20 17 , 20 -lyase and 11 β 11\beta 11 β -hydroxylase ), causing gynecomastia, decreased libido, and adrenal insufficiency . Retained as 2 % 2\% 2% shampoo for seborrheic dermatitis.

Loading diagram... Fungal Cell Target Sites and Pharmacologic Mechanisms

  • Cell Membrane Pore Formers & Cell Wall Synthesis Inhibitors
  • Polyenes: Amphotericin B & Nystatin
  • Amphotericin B

Amphotericin B is an amphoteric polyene macrolide containing a hydrophobic conjugated polyene chain and a hydrophilic polyol chain.

Mechanism of Action: Amphotericin B binds directly with high affinity to ergosterol in fungal cell membranes. Several amphotericin molecules aggregate to form a cylindrical transmembrane micropore or ion channel. This creates membrane permeability, permitting rapid efflux of intracellular potassium ( K + K^+ K + ) and magnesium ( M g 2 + Mg^{2+} M g 2 + ) , collapsing electrochemical gradients and causing rapid fungal cell death (fungicidal).

Selectivity: Preferentially binds fungal ergosterol over human cholesterol; however, cross-binding to human cholesterol in renal tubular cell membranes accounts for profound host toxicity.

Clinical Indications: Life-threatening systemic mycoses, including invasive mucormycosis (rhinocerebral/lower extremity Rhizopus in diabetic ketoacidosis), disseminated blastomycosis, histoplasmosis, coccidioidomycosis, and severe cryptococcal meningitis.

Adverse Effects (The "Ampho-Terrible" Profile):

Immediate Infusion Reactions: "Shake and bake" cytokine release—severe chills, rigors, fever, headache, nausea, and bronchospasm (prevented by premedication with acetaminophen, diphenhydramine, and meperidine/hydrocortisone).

Renal Tubular Toxicity: Binds tubular epithelial cells, causing afferent arteriolar vasoconstriction (prerenal azotemia) and distal renal tubular acidosis (Type 1 RTA). Leads to severe hypokalemia , hypomagnesemia , and tubular nephrocalcinosis.

Normocytic Normochromic Anemia: Inhibits renal erythropoietin synthesis.

Liposomal Formulations (AmBisome): Packaging the drug in liposomal lipid spheres reduces direct contact with human renal membranes, significantly decreasing nephrotoxicity while preserving antifungal efficacy (at significantly higher drug cost).

Nystatin

Nystatin shares the identical polyene pore-forming mechanism of amphotericin B. However, it is severely toxic if administered parenterally (causes catastrophic systemic hemolysis). It is strictly limited to topical and oral suspension ("swish and swallow") for superficial cutaneous candidiasis, angular cheilitis, and oral thrush ( Candida albicans ).

Echinocandins: Caspofungin, Micafungin, Anidulafungin

Echinocandins are large, cyclic lipopeptides that inhibit the synthesis of β \beta β -(1,3)-D-glucan , an essential structural polysaccharide component of the fungal cell wall (catalyzed by β \beta β -(1,3)-D-glucan synthase ).

Effect: Weakens the rigid fungal cell wall, leading to osmotic instability and rapid cellular lysis ( fungicidal against Candida species, including azole-resistant strains; fungistatic against Aspergillus ).

Human Safety: Because human cells possess cell membranes but completely lack cell walls and glucan polymers, echinocandins display an exceptional safety profile with minimal organ toxicity.

Route: Administered IV only ; not orally absorbed. Minimal CYP450 interactions. Mild histamine release with rapid infusion.

Topical Therapeutics for Onychomycosis & Tinea Pedis

Topical therapy for onychomycosis avoids the hepatotoxicity and drug interactions of systemic terbinafine/azoles, but is hindered by poor transungual drug penetration through the dense, keratinized dorsal nail plate. Three FDA-approved prescription topicals exhibit specific mechanisms to overcome this barrier:

Topical Formulation Drug Class Biochemical Mechanism of Action Pharmacokinetics & Board Pearls

Ciclopirox 8% Nail Lacquer (Penlac) Hydroxypyridone Chelates trivalent polyvalent cations ( F e 3 + , A l 3 + Fe^{3+}, Al^{3+} F e 3 + , A l 3 + ) , inhibiting metal-dependent fungal enzymes (catalase, peroxidase, cytochrome electron transport) and nutrient transport. Formulated as an evaporating ethyl acetate lacquer; applied once daily to the entire nail plate and under the free edge for 48 weeks 48\text{ weeks} 48 weeks . Lacquer film builds up and must be removed with isopropyl alcohol once weekly . Modest mycological cure rate ( 29 − 36 % 29 - 36\% 29 − 36% ).

Efinaconazole 10% Solution (Jublia) Triazole Inhibits fungal lanosterol 14- α \alpha α -demethylase ; specially formulated with a hydrocarbon vehicle that confers extremely low binding affinity for keratin . Because it does not bind tightly to keratin, free drug rapidly diffuses through the full thickness of the nail plate into the underlying nail bed. Applied daily with flow-through brush for 48 weeks 48\text{ weeks} 48 weeks . No debridement or lacquer stripping required. Higher cure rates ( 50 − 55 % 50 - 55\% 50 − 55% mycological cure).

Tavaborole 5% Solution (Kerydin) Oxaborole (Boron-containing) Inhibits fungal leucyl-transfer RNA (tRNA) synthetase , trapping tRNA and terminating fungal protein translation. Boron chemistry confers a very low molecular weight ( 152 Da 152\text{ Da} 152 Da ) , allowing deep transungual penetration through dense nail plate keratin without binding. Applied once daily for 48 weeks 48\text{ weeks} 48 weeks . Excellent safety; adverse effects limited to local periungual erythema and dermatitis.

Note

Topical Agents for Tinea Pedis: Interdigital and moccasin-type tinea pedis respond well to topical allylamines ( Terbinafine 1% cream , Butenafine 1% cream — superior fungicidal cure and lower recurrence) or topical azoles ( Clotrimazole 1% , Miconazole 2% , Econazole 1% , Luliconazole 1% — fungistatic, requires 2 to 4 weeks of consistent twice-daily application). Tolnaftate is a non-prescription thiocarbamate that also inhibits squalene epoxidase.

Antiviral Therapeutics in Podiatric Care

Podiatric physicians frequently diagnose and manage cutaneous viral infections of the lower extremity, predominantly Herpesviridae (Herpes Simplex Virus [HSV-1, HSV-2] and Varicella-Zoster Virus [VZV shingles]) and Human Papillomavirus (HPV, producing Verruca plantaris) .

Guanosine Analogs: Acyclovir, Valacyclovir & Famciclovir Activation Cascade of Acyclovir / Valacyclovir

  • Acyclovir (or Valacyclovir prodrug)
  • │
  • ▼ ◄── Viral Thymidine Kinase (TK) [RATE-LIMITING]
  • Acyclovir Monophosphate
  • │
  • ▼ ◄── Host Cellular Kinases
  • Acyclovir Diphosphate
  • │
  • ▼ ◄── Host Cellular Kinases
  • Acyclovir Triphosphate (Active Form)
  • │
  • ┌───────────┴───────────┐
  • ▼ ▼
  • Competitive Inhibition Obligate DNA Chain Termination
  • of Viral DNA Polymerase (Lacks 3'-OH group for phosphodiester bond)
  • Mechanism of Action

Monophosphorylation by Viral Thymidine Kinase (TK): Acyclovir is an acyclic guanosine nucleoside analog. It is taken up by virus-infected cells and converted to acyclovir monophosphate exclusively by viral Thymidine Kinase . Uninfected human cells lack this enzyme, providing exquisite drug selectivity.

Triphosphate Generation: Host cellular kinases convert the monophosphate into acyclovir diphosphate, and finally into the active compound: Acyclovir Triphosphate .

Dual Inhibition:

Competitively inhibits viral DNA Polymerase .

Incorporates into the replicating viral DNA strand. Because acyclovir completely lacks a 3'-hydroxyl (3'-OH) group , the viral DNA polymerase cannot form the next 3'-to-5' phosphodiester bond, resulting in obligate, irreversible chain termination .

Agents & Pharmacokinetics

Acyclovir (Zovirax): Poor oral bioavailability ( F ≈ 15 − 20 % F \approx 15 - 20\% F ≈ 15 − 20% ); requires frequent dosing (5 times daily for acute outbreaks).

Valacyclovir (Valtrex): L-valyl ester prodrug of acyclovir. Rapidly hydrolyzed by first-pass hepatic esterases into active acyclovir, delivering 3- to 5-fold higher oral bioavailability ( F ≈ 55 % F \approx 55\% F ≈ 55% ) with convenient BID to TID dosing. First-line oral therapy for Herpes Zoster (Shingles) involving lower extremity dermatomes (L4, L5, S1) to prevent postherpetic neuralgia .

Famciclovir (Famvir): Diacetyl prodrug of penciclovir; prolonged intracellular half-life.

Adverse Effects & Toxicities

Obstructive Crystalline Nephropathy: High-dose IV acyclovir exceeds urinary solubility in the renal collecting duct, precipitating insoluble acyclovir needle-shaped crystals within the renal tubular lumen. Manifests as rapid acute kidney injury with elevated creatinine within 24 to 48 hours. Prevention: Maintain aggressive intravenous hydration and slow IV infusion over ≥ 1 \ge 1 ≥ 1 hour.

Neurotoxicity: Confusion, delirium, visual hallucinations, and myoclonus; observed primarily in elderly patients or patients with renal failure without dose reduction.

Mechanism of Acyclovir Resistance & Foscarnet

Resistance develops almost exclusively through mutations in the viral genome producing deficiency or structural alteration of viral Thymidine Kinase (TK-negative strains) . Because TK-negative strains cannot monophosphorylate acyclovir, the drug remains inactive.

Foscarnet (Foscavir): An inorganic pyrophosphate analog that directly inhibits viral DNA polymerase by reversibly binding to the pyrophosphate-binding site without requiring ANY intracellular phosphorylation or viral thymidine kinase. Drug of choice for acyclovir-resistant, TK-negative HSV and VZV (also treats CMV retinitis). Highly toxic: severe nephrotoxicity and electrolyte chelation ( hypocalcemia, hypomagnesemia, hypokalemia ).

Cidofovir: Acyclic nucleoside phosphonate; already contains a phosphate-mimicking phosphonate group, requiring only host cellular kinases (independent of viral TK).

Plantar Verrucae (HPV) Pharmacotherapy

Plantar warts ( Verruca plantaris ) are intraepidermal benign neoplasms caused by infection of basal keratinocytes with Human Papillomavirus (primarily HPV types 1, 2, 4, 27, and 57) . Podiatric management combines mechanical debridement, chemical cautery, antineoplastic agents, and immunomodulators:

Therapeutic Modality Active Agent Primary Mechanism of Action Clinical Application & Safety

Keratolytic Therapy Salicylic Acid (17% to 40%) Solubilizes intercellular stratum corneum desmosomes; macerates and sheds infected keratinocytes; induces low-level inflammatory clearance. Applied topically under occlusion daily following aggressive sharp debridement. Safe, painless, first-line home therapy.

Vesicant / Blistering Cantharidin (0.7% solution) Terpenoid extracted from blister beetles ( Cantharis vesicatoria ); inhibits protein phosphatases 1 and 2A (PP1/PP2A) , dissolving desmosomes to cause acantholysis and intraepidermal blister formation . Applied topically in-office; painless on application, but produces an intraepidermal blister within 24–48 hours that lifts the wart off the dermis. Minimal risk of scarring (remains intraepidermal).

Topical Immunomodulation Imiquimod 5% Cream (Aldara) Toll-Like Receptor 7 (TLR7) agonist ; stimulates local Langerhans cells and monocytes to secrete Interferon-alpha (IFN- α \alpha α ), TNF- α \alpha α , IL-12 , activating cytotoxic CD8+ T cells against HPV. Applied topically under occlusion 3 times weekly for recalcitrant verrucae. Can trigger local erythema, erosions, and flu-like symptoms.

Intralesional Antineoplastic Bleomycin ( 1 U/mL 1\text{ U/mL} 1 U/mL injection) Glycopeptide antitumor antibiotic; complexes with F e 2 + Fe^{2+} F e 2 + , generates reactive oxygen species (ROS) that cleave host/viral DNA ; causes acute endothelial damage, microthrombi, and tissue necrosis. Injected intralesionally for stubborn, mosaic recalcitrant plantar warts. High cure rate ( > 85 % >85\% > 85% ). High-yield warning: can cause digital vasospasm, permanent nail dystrophy (if near matrix), and intense local ischemic pain.

Antimetabolite 5-Fluorouracil (5-FU) (5% cream / intralesional) Pyrimidine analog; inhibits thymidylate synthase , depleting dTMP and halting DNA replication in hyperproliferating verrucous keratinocytes. Often combined with salicylic acid. Applied under duct-tape occlusion. Contraindicated in pregnancy (teratogenic).

Antiprotozoal and Antiparasitic Agents

Drug Mechanism Main uses Key adverse effects

Metronidazole Reduced inside anaerobes to free radicals that damage DNA Anaerobes ( Bacteroides , C. difficile ), Trichomonas , Giardia , amebiasis Metallic taste; disulfiram-like reaction with alcohol is traditionally warned; peripheral neuropathy with prolonged courses; raises warfarin effect

Ivermectin Opens glutamate-gated chloride channels in invertebrate nerve and muscle Strongyloides , onchocerciasis, scabies (oral, including crusted scabies), cutaneous larva migrans Usually mild; Mazzotti reaction in heavy filarial infection

Permethrin 5% cream Prolongs sodium channel opening in arthropod nerves Scabies (first-line topical, neck to soles including the toe webs), lice Local burning and itch

Albendazole and mebendazole Bind beta-tubulin in helminths, blocking microtubule formation and glucose uptake Hookworm, ascaris, pinworm, cutaneous larva migrans (albendazole), neurocysticercosis Abdominal pain; bone marrow suppression and liver enzyme elevation with long courses; avoid in pregnancy

Praziquantel Increases calcium permeability in the worm, causing paralysis Schistosomes, tapeworms, flukes Dizziness, abdominal pain

Chloroquine and hydroxychloroquine Prevent heme detoxification (polymerization) in the malaria parasite Malaria prophylaxis or treatment where sensitive; hydroxychloroquine also for lupus and rheumatoid arthritis Retinopathy (screen the eyes), QT prolongation, hemolysis in G6PD deficiency

Primaquine Kills liver-stage hypnozoites Relapse prevention in P. vivax and P. ovale malaria Hemolysis in G6PD deficiency (test first), methemoglobinemia

TMP-SMX and pyrimethamine Block folate synthesis Pneumocystis and Toxoplasma Rash, cytopenias, hyperkalemia; give leucovorin with pyrimethamine

Scabies management. Treat the patient and close contacts at the same time. Apply permethrin from the neck to the soles and repeat in 7–14 days. Wash bedding and clothing in hot water. Itching can persist for weeks after cure because of hypersensitivity to mite remnants.